EGFR mutation analysis in sputum of lung cancer patients: A multitechnique study

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 38-43

  Hubers, A Jasmijn ^a   Heideman, Daniëlle A M ^a   Yatabe, Yasushi ^b   Wood, Michelle D ^c   Tull, Justyna ^c   Tarón, Miquel ^d,e   Molina, Miquel A ^e   Mayo, Clara ^e   Bertran Alamillo, Jordi ^e   Herder, Gerarda J M ^f   Koning, Remco ^a   Sie, Daoud ^a   Ylstra, Bauke ^a   Meijer, Gerrit A ^a   Snijders, Peter J F ^a   Witte, Birgit I ^a   Postmus, Pieter E ^a   Smit, Egbert F ^a   Thunnissen, Erik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e INSTITUT UNIVERSITARI DEXEUS   (Spain)

^f ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Analysis of sputum; Epidermal growth factor receptor (EGFR); Genomics; Lung cancer diagnosis; Molecular diagnostics; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; LUNG CANCER; MALE; MULTICENTER STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPUTUM; SPUTUM ANALYSIS;

ANALYSIS OF SPUTUM; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); GENOMICS; LUNG CANCER DIAGNOSIS; MOLECULAR DIAGNOSTICS; NON-SMALL CELL LUNG CANCER; TYROSINE KINASE INHIBITORS;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; DNA; DNA MUTATIONAL ANALYSIS; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS, SQUAMOUS CELL; POLYMERASE CHAIN REACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; SPUTUM; TRANSITION TEMPERATURE;

EID: 84884417198     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.011     Document Type: Article

References (48)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
3. Smouse J.H., Cibas E.S., Jänne P.A., Joshi V.A., Zou K.H., Lindeman N.I. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009, 117:67-72.
4. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
5. Chowdhuri S.R., Xi L., Pham T.H.-T., Hanson J., Rodriguez-Canales J., Berman A., et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Modern Pathol 2012, 25:548-555.
6. Rivera M.P., Mehta A.C. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed.). Chest 2007, 132:131S-148S.
7. Mao L., Hruban R.H., Boyle J.O., Tockman M., Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994, 54:1634-1637.
8. Destro A., Bianchi P., Alloisio M., Laghi L., Di Gioia S., Malesci A., et al. K-ras and p16(INK4A) alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 2004, 44:23-32.
9. Somers V.A., Pietersen A.M., Theunissen P.H., Thunnissen F.B. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. J Clin Oncol 1998, 16:3061-3068.
10. Belinsky S.A., Grimes M.J., Casas E., Stidley C.A., Franklin W.A., Bocklage T.J., et al. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007, 96:1278-1283.
11. Belinsky S.A., Klinge D.M., Dekker J.D., Smith M.W., Bocklage T.J., Gilliland F.D., et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005, 11:6505-6511.
12. Honorio S., Agathanggelou A., Schuermann M., Pankow W., Viacava P., Maher E.R., et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003, 22:147-150.
13. Hwang S.-H., Kim K.U., Kim J.-E., Kim H.-H., Lee M.K., Lee C.H., et al. Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. Clin Chem Lab Med 2011, 49:699-704.
14. Kersting M., Friedl C., Kraus A., Behn M., Pankow W., Schuermann M. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000, 18:3221-3229.
15. Shivapurkar N., Stastny V., Suzuki M., Wistuba I.I., Li L., Zheng Y., et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 2007, 247:56-71.
16. Tessema M., Klinge D.M., Yingling C.M., Do K., Van Neste L., Belinsky S.A. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 2010, 29:5159-5170.
17. Tanaka T., Matsuoka M., Sutani A., Gemma A., Maemondo M., Inoue A., et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010, 126:651-655.
18. Boldrini L., Gisfredi S., Ursino S., Camacci T., Baldini E., Melfi F., et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007, 2:1086-1090.
19. Takano T., Ohe Y., Tsuta K., Fukui T., Sakamoto H., Yoshida T., et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. Clin Cancer Res 2007, 13:5385-5390.
20. Hubers A.J., Heideman D.A.M., Herder G.J.M., Burgers S.A., Sterk P.J., Kunst P.W., et al. Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. J Clin Pathol 2012, 65:541-545.
21. Heideman D.A.M., Thunnissen F.B., Doeleman M., Kramer D., Verheul H.M., Smit E.F., et al. A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol 2009, 31:329-333.
22. Kramer D., Thunnissen F.B., Gallegos-Ruiz M.I., Smit E.F., Postmus P.E., Meijer C.J.L.M., et al. A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cell Oncol 2009, 31:161-167.
23. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23:857-865.
24. Rekhtman N., Paik P.K., Arcila M.E., Tafe L.J., Oxnard G.R., Moreira A.L., et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012, 18:1167-1176.
25. Sobin L.H. TNM classification of malignant tumours 2009, Wiley-Blackwell.
26. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
27. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
28. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
29. Zhou C., Wu Y.-L., Chen G., Feng J., Liu X.-Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
30. Yatabe Y., Hida T., Horio Y., Kosaka T., Takahashi T., Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006, 8:335-341.
31. Li J., Wang L., Jänne P.A., Makrigiorgos G.M. Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. Clin Chem 2009, 55:748-756.
32. Li J., Milbury C.A., Li C., Makrigiorgos G.M. Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. Hum Mutat 2009, 30:1583-1590.
33. Li J., Makrigiorgos G.M. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Biochem Soc Trans 2009, 37:427-432.
34. Li J., Wang L., Mamon H., Kulke M.H., Berbeco R., Makrigiorgos G.M. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008, 14:579-584.
35. Tanaka T., Nagai Y., Miyazawa H., Koyama N., Matsuoka S., Sutani A., et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007, 98:246-252.
36. Kim S.T., Jung H.-Y., Sung J.S., Jo U.H., Tanaka T., Hagiwara K., et al. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?. Am J Clin Oncol 2012.
37. Jiang B., Liu F., Yang L., Zhang W., Yuan H., Wang J., et al. Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 2011, 39:1392-1401.
38. Brevet M., Johnson M.L., Azzoli C.G., Ladanyi M. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011, 73:96-102.
39. He C., Liu M., Zhou C., Zhang J., Ouyang M., Zhong N., et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009, 125:2393-2399.
40. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
41. Yun C.-H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.-K., et al. The T790 M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075.
42. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
43. Miyazawa H., Tanaka T., Nagai Y., Matsuoka M., Sutani A., Udagawa K., et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790 M epidermal growth factor receptor mutation. Cancer Sci 2008, 99:595-600.
44. Thunnissen F.B.J.M. Sputum examination for early detection of lung cancer. J Clin Pathol 2003, 56:805-810.
45. Ammanagi A.S., Dombale V.D., Miskin A.T., Dandagi G.L., Sangolli S.S. Sputum cytology in suspected cases of carcinoma of lung (sputum cytology a poor man's bronchoscopy!). Lung India 2012, 29:19-23.
46. Petrelli F., Borgonovo K., Cabiddu M., Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012, 13:107-114.
47. Gao G., Ren S., Li A., Xu J., Xu Q., Su C., et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 2012, 131:E822-E829.
48. Gold P.M. The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care 2009, 54:1040-1049.